Anyone want to place a bet on this one. If the assay looks as good as the core the pay off will be bigger than any mine could produce.Trading at ~$0.20 with ~20 mil shares for a market cap of $4 mil.
IMM-V
INR's Virus Neutralizing Antibody Research Project
The study of mAb IF7
Research related to the safety/feasibility study of mAb IF7 in non-human primates macaque monkeys revealed that the mAb IF7 injection increased virus-neutralizing antibody levels in macaques chronically infected with SHIVIIIB - a recombinant retrovirus designed to allow study of anti-HIV immune responses in macaque monkeys. This work is carried out under the direction of Drs. Sybille Müller and Heinz Köhler of the University of Kentucky, in collaboration with scientists at the New England Regional Primate Center and Dr. Norman Letvin from the US National Cancer Institute (one of the world's leading experts in animal models of AIDS). Laboratory analysis of plasma samples taken from the macaques receiving mAb IF7 revealed a rapid rise in the potency of antibody neutralization of HIVIIIB following the mAb IF7 injection. This reaction indicates that mAb IF7 stimulates new production of broadly neutralizing anti-HIV antibodies in the infected macaques.
Project History
Phase I - Completed Successfully
The Phase I primate study demonstrated a potential breakthrough in the immunotherapy of HIV infection. In the Phase I study, beneficial effects on the immune system of SHIV infected macaques were observed and mAb IF7 was noted to have enhanced the immune response against the viral infection in the macaques. The results of this study were published in the prestigious "Proceedings of the National Academy of Sciences USA" (PNAS Vol. 95 pp. 276-281, January 6, 1998).
Phase II - Near Completion
The Phase II primate study is showing encouraging results as demonstrated by the condition of the macaques. In response, ImmPheron, Inc. (INR's joint venture partner) produced additional mAb IF7 and selected animals received a second series of injections to model repeated treatments in chronically-infected humans.
The Phase II primate study was launched on the basis of promising results from the Phase I study, which demonstrated that mAb IF7 increased the breadth and potency of virus neutralizing antibodies, the defensive agents produced by the immune system which inhibit, or neutralize, HIV. The Phase II study is under the direction of Dr. Sybille Muller, Vice President of ImmPheron, Inc. ImmPheron, by funding this program, is earning an equal interest in the application of mAb IF7 towards the treatment of HIV infection.
The Phase II primate study is evaluating mAb IF7 for use as a therapeutic for human disease caused by the HIV and AIDS. The study, which is being carried out at the Oregon Regional Primate Center, involves a total of nine macaques. Four SHIV 89.6P-infected and two healthy macaques received a series of five injections of mAb IF7. Three other SHIV89.6P-infected animals received control injections. The macaques are being closely observed for any changes in disease status. Whole blood, plasma, and tissue sampling over the six month duration of the study will provide important data on T-cell subset normalization, viral load and virus neutralizing antibody levels to determine whether mAb IF7 promotes restoration of an already impaired immune system.
The key analysis of the viral load of the macaques will be carried out once all sample collection is complete. The current primate study will also provide important toxicity data, which is a prerequisite for approval of an Investigational New Drug (IND) trial.
Application for Investigational New Drug (IND)
INR expects to complete a research milestone this year by completing the application for an Investigational New Drug (IND), either in Canada or the United States to evaluate the use of mAb IF7 as an immune-based therapeutic for HIV infection.
Data from the initial study and the preliminary indications from the Phase II primate study support corporate plans for both continued research and the preparation for an initial clinical trial of mAb IF7 as an Investigational New Drug (IND) in humans. Preliminary discussions are being held with various research organizations and the FDA regarding the requirements and conditions for a clinical trial.
immunenetwork.com
The study has been completed and results are expected in November and if successful this will be big "News that catches your eye".
Expect to see some big volatility as we come down to the wire - I have flipped this one several times for good profit but maintain a core holding.
John |
